99.3% PURITY LOT VL-2961-A Semax
A synthetic ACTH(4-10) peptide analog supplied as a 10 mg lyophilized vial for research into cognition, attention, and neuroprotection.
- 1 × Semax 10mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
About this compound
A synthetic ACTH(4-10) peptide analog supplied as a 10 mg lyophilized vial for research into cognition, attention, and neuroprotection.
- 10 mg lyophilized peptide per vial
- Synthetic ACTH(4-10) analog (Semax)
- Synthetic peptide, ≥99% purity
- Studied for BDNF/NGF expression, neuroprotection and cognition
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Current lot snapshot
Shipping
Reported use in research
Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment, comprising the sequence Met-Glu-His-Phe-Pro-Gly-Pro. In research settings it is investigated as a nootropic and neuroprotective agent, with studies focusing on its influence on neurotrophic signaling pathways. Preclinical models have explored its reported ability to modulate the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). The peptide is studied for its potential role in cognition, attention, and cellular resilience within the central nervous system. It is supplied as a lyophilized powder intended solely for controlled laboratory investigation.
Reported findings
Research reports that Semax may increase the expression of BDNF and NGF in preclinical models, signaling molecules associated with neuronal survival and plasticity. Animal research models have investigated its reported neuroprotective effects under conditions of ischemia and oxidative stress. Additional studies have examined its potential influence on attention, memory consolidation, and learning behavior. These properties have positioned Semax as a subject of interest in nootropic and neuroprotection research models.
Handling & safety
The full safety and toxicological profile of Semax has not been completely characterized in research models. Handling should follow standard laboratory safety practices, including the use of appropriate personal protective equipment. As with all research peptides, it should be managed only by qualified personnel in a controlled environment. This compound is not intended for any use outside of scientific investigation.
Reconstitution
Recommended ratio
- 1 mL of bacteriostatic water per 10 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 813.9 g/mol | PASS |
| Purity | HPLC (area %) | 99.3% | PASS |
| Net peptide content | Gravimetric | 10.02 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 813.9 g/mol | PASS |
| Purity | HPLC (area %) | 99.2% | PASS |
| Net peptide content | Gravimetric | 10.01 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2961-A | Jul 2026 | 99.3% | TR-88625 | Active | |
| VL-2942-B | May 2026 | 99.2% | TR-88540 | Sold out |
